Trial 0C-23-14


A Phase 1 First-In-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy, Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Mary Ordaz, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Niranjan Bhatt, D.M., Negeen Izadian, Coordinator, Clara Karam, D.M., Nazeli Livaskani, Coordinator, Stephanie Kim, Coordinator, Alexandra Artura, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.